early on to identify unmet needs and opportunities Discussing the future of pre-filled syringe injection devices, with representatives from AbbVie, Pfizer, Genentech, Ferring Pharmaceuticals ...

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

VYVGART ® Hytrulo prefilled syringe for self-injection is approved ... patient lives in post-marketing use in ten commercialized products across more than 100 global markets, Halozyme has ...

AbbVie ABBV reported 8.4% revenue growth and ... and management’s combined $900 million guidance raise for these two products more than offset the $500 million lower Humira guidance due to ...

Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.

AbbVie Inc. raised its profit outlook for the year on better-than-expected sales from newer autoimmune treatments, but warned its forecast doesn’t take into account any potential changes in ...